PL2056845T3 - Struktura i zastosowanie oligonukleotydów z 5'-fosforanem - Google Patents

Struktura i zastosowanie oligonukleotydów z 5'-fosforanem

Info

Publication number: PL2056845T3
Authority: PL; Poland
Prior art keywords: phosphate oligonucleotides; oligonucleotides; phosphate
Prior art date: 2006-08-08

Application number

PL07801562T

Other languages

English (en)

Inventor

Veit Hornung

Gunther Hartmann

Original Assignee

Univ Bonn Rheinische Friedrich Wilhelms

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-08

Filing date

2007-08-08

Publication date

2018-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38875059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2056845(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-10-10 Priority claimed from EP06021271A external-priority patent/EP1920775B1/en

2007-08-08 Application filed by Univ Bonn Rheinische Friedrich Wilhelms filed Critical Univ Bonn Rheinische Friedrich Wilhelms

2018-01-31 Publication of PL2056845T3 publication Critical patent/PL2056845T3/pl

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
229910019142 PO4 Inorganic materials 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
239000010452 phosphate Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Microbiology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL07801562T 2006-08-08 2007-08-08 Struktura i zastosowanie oligonukleotydów z 5'-fosforanem PL2056845T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP06016578		2006-08-08
EP06021271A EP1920775B1 (en)	2006-10-10	2006-10-10	5'Triphosphate oligonucleotide induces anti-viral response
PCT/EP2007/007024 WO2008017473A2 (en)	2006-08-08	2007-08-08	Structure and use of 5' phosphate oligonucleotides
EP07801562.5A EP2056845B1 (en)	2006-08-08	2007-08-08	Structure and use of 5' phosphate oligonucleotides

Publications (1)

Publication Number	Publication Date
PL2056845T3 true PL2056845T3 (pl)	2018-01-31

Family

ID=38875059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07801562T PL2056845T3 (pl)	2006-08-08	2007-08-08	Struktura i zastosowanie oligonukleotydów z 5'-fosforanem

Country Status (14)

Country	Link
US (3)	US20100178272A1 (pl)
EP (3)	EP2056845B1 (pl)
JP (6)	JP2010500011A (pl)
AU (1)	AU2007283022B2 (pl)
CA (1)	CA2660232C (pl)
CY (1)	CY1119608T1 (pl)
DK (1)	DK2056845T3 (pl)
ES (2)	ES2911034T3 (pl)
HU (1)	HUE037173T2 (pl)
LT (1)	LT2056845T (pl)
PL (1)	PL2056845T3 (pl)
PT (1)	PT2056845T (pl)
SI (1)	SI2056845T1 (pl)
WO (1)	WO2008017473A2 (pl)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010500011A (ja)	2006-08-08	2010-01-07	ガンサーハートマン	５’リン酸オリゴヌクレオチドの構造および使用
EP2338499A1 (en)	2006-10-10	2011-06-29	Gunther Hartmann	5' triphosphate oligonucleotide induces anti-viral response
US20120177610A1 (en)	2007-09-19	2012-07-12	Kieu Hoang	Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins
CN101424640B (zh)	2007-11-02	2012-07-25	江苏命码生物科技有限公司	血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
DK2518150T3 (en)	2008-05-21	2015-12-07	Univ Bonn	5'Trip phosphate triphosphate oligonucleotide and uses thereof
JP2017006144A (ja) *	2008-05-21	2017-01-12	ライニッシュフリードリッヒ−ウィルヘルムズ−ユニバーシタットボン	平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
US9738680B2 (en)	2008-05-21	2017-08-22	Rheinische Friedrich-Wilhelms-Universität Bonn	5′ triphosphate oligonucleotide with blunt end and uses thereof
WO2010002851A1 (en) *	2008-06-30	2010-01-07	Alnylam Pharmaceuticals, Inc.	Silencing and rig-1 activation by dual function oligonucleotides
WO2010085665A2 (en) *	2009-01-23	2010-07-29	Cedars-Sinai Medical Center	Targeted delivery system
EP3263707A1 (en)	2009-03-17	2018-01-03	Rheinische Friedrich-Wilhelms-Universität Bonn	Tlr8 ligand and uses thereof
WO2011066651A1 (en) *	2009-12-01	2011-06-09	Protiva Biotherapeutics, Inc.	Snalp formulations containing antioxidants
WO2011106104A2 (en) *	2010-02-26	2011-09-01	Memorial Sloan-Kettering Cancer Center	Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets
WO2011114346A1 (en)	2010-03-18	2011-09-22	Chetan Balar	Chitin and related compounds for use in treating bacterial and viral infections
US20120009130A1 (en) *	2010-05-06	2012-01-12	Nanoaxis	Viral Therapy and Prophylaxis Using Nanotechnology Delivery Techniques
CN101892241B (zh) *	2010-07-09	2013-01-09	电子科技大学	一种草鱼白细胞介素1β基因和蛋白及其重组表达方法
US9040234B2 (en)	2010-08-30	2015-05-26	Spring Bank Pharmaceuticals, Inc.	Oligonucleotide analogs as therapeutic agents
EP2508530A1 (en)	2011-03-28	2012-10-10	Rheinische Friedrich-Wilhelms-Universität Bonn	Purification of triphosphorylated oligonucleotides using capture tags
CA2831613A1 (en)	2011-03-31	2012-10-04	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US8916352B2 (en) *	2011-04-08	2014-12-23	Bio-Rad Laboratories, Inc.	PCR reaction mixtures with decreased non-specific activity
US9844592B2 (en) *	2011-07-18	2017-12-19	Icahn School Of Medicine At Mount Sinai	Bacterial RNAs as vaccine adjuvants
JP2014532400A (ja)	2011-10-31	2014-12-08	リボックス・ゲーエムベーハー	免疫賦活用の二本鎖ｒｎａ
WO2013097965A1 (en)	2011-12-30	2013-07-04	Riboxx Gmbh	Triphosphate-containing double-stranded rna for immunostimulation
TW201335181A (zh) *	2012-01-31	2013-09-01	Kieu Hoang	５５種新發現的蛋白質之序列及其應用
EP2712870A1 (en) *	2012-09-27	2014-04-02	Rheinische Friedrich-Wilhelms-Universität Bonn	Novel RIG-I ligands and methods for producing them
US20140287023A1 (en) *	2013-02-11	2014-09-25	Mcgill University	5'-triphosphate oligoribonucleotides
US10077439B2 (en) *	2013-03-15	2018-09-18	Modernatx, Inc.	Removal of DNA fragments in mRNA production process
EP2971033B8 (en)	2013-03-15	2019-07-10	ModernaTX, Inc.	Manufacturing methods for production of rna transcripts
EP4279610A3 (en)	2013-03-15	2024-01-03	ModernaTX, Inc.	Ribonucleic acid purification
WO2014144767A1 (en)	2013-03-15	2014-09-18	Moderna Therapeutics, Inc.	Ion exchange purification of mrna
PL3019619T3 (pl)	2013-07-11	2022-01-10	Modernatx, Inc.	Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
KR102160389B1 (ko)	2013-08-05	2020-09-28	트위스트 바이오사이언스 코포레이션	드 노보 합성된 유전자 라이브러리
US10457946B2 (en) *	2013-09-16	2019-10-29	St. Jude Children's Research Hospital, Inc.	Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer
EP3083962B1 (en) *	2013-12-16	2021-08-18	RiboxX GmbH	Double-stranded polyc:poly(g/i) rna for immunostimulation and cancer treatment
JP2015142566A (ja) *	2013-12-26	2015-08-06	国立大学法人鹿児島大学	養魚用飼料
US10286086B2 (en)	2014-06-19	2019-05-14	Modernatx, Inc.	Alternative nucleic acid molecules and uses thereof
US9670489B2 (en) *	2014-07-14	2017-06-06	Kaohsiung Medical University	Method for treating and/or preventing myopia
AU2015289656A1 (en)	2014-07-16	2017-02-16	Modernatx, Inc.	Circular polynucleotides
EP3172324A4 (en)	2014-07-18	2018-04-25	Oregon Health & Science University	5'-triphosphate oligoribonucleotides
CA2975852A1 (en)	2015-02-04	2016-08-11	Twist Bioscience Corporation	Methods and devices for de novo oligonucleic acid assembly
CA2975855C (en)	2015-02-04	2025-09-23	Twist Bioscience Corporation	SYNTHETIC GENE COMPOSITIONS AND ASSEMBLY METHODS
WO2016172377A1 (en)	2015-04-21	2016-10-27	Twist Bioscience Corporation	Devices and methods for oligonucleic acid library synthesis
EP4101930A1 (en)	2015-09-17	2022-12-14	ModernaTX, Inc.	Polynucleotides containing a stabilizing tail region
WO2017049286A1 (en)	2015-09-17	2017-03-23	Moderna Therapeutics, Inc.	Polynucleotides containing a morpholino linker
KR20180050411A (ko)	2015-09-18	2018-05-14	트위스트 바이오사이언스 코포레이션	올리고핵산 변이체 라이브러리 및 그의 합성
WO2017053450A1 (en)	2015-09-22	2017-03-30	Twist Bioscience Corporation	Flexible substrates for nucleic acid synthesis
KR101899057B1 (ko)	2015-10-15	2018-09-14	한국과학기술원	Rna 올리고뉴클레오티드를 포함하는 암 치료용 약학 조성물
WO2017065405A1 (ko)	2015-10-15	2017-04-20	한국과학기술원	Rna 올리고뉴클레오티드를 포함하는 항바이러스제
WO2017065369A1 (ko) *	2015-10-15	2017-04-20	한국과학기술원	Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제
KR101842679B1 (ko)	2015-10-15	2018-03-28	한국과학기술원	Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제
KR101881502B1 (ko)	2015-10-15	2018-07-25	한국과학기술원	Rna 올리고뉴클레오티드를 포함하는 항바이러스제
EP3384077A4 (en)	2015-12-01	2019-05-08	Twist Bioscience Corporation	FUNCTIONALIZED SURFACES AND MANUFACTURE THEREOF
US12385034B2 (en)	2016-06-24	2025-08-12	Modernatx, Inc.	Methods and apparatus for filtration
WO2018038772A1 (en)	2016-08-22	2018-03-01	Twist Bioscience Corporation	De novo synthesized nucleic acid libraries
EP4664304A3 (en)	2016-09-21	2026-01-21	Atlas Data Storage, Inc.	Nucleic acid based data storage
GB2573069A (en)	2016-12-16	2019-10-23	Twist Bioscience Corp	Variant libraries of the immunological synapse and synthesis thereof
WO2018156792A1 (en)	2017-02-22	2018-08-30	Twist Bioscience Corporation	Nucleic acid based data storage
CA3056388A1 (en)	2017-03-15	2018-09-20	Twist Bioscience Corporation	Variant libraries of the immunological synapse and synthesis thereof
WO2018172546A1 (en)	2017-03-24	2018-09-27	Rigontec Gmbh	Method for designing rig-i ligands
BR112019021520A2 (pt)	2017-04-14	2020-08-04	Tollnine, Inc.	oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
WO2018231864A1 (en)	2017-06-12	2018-12-20	Twist Bioscience Corporation	Methods for seamless nucleic acid assembly
IL271205B2 (en)	2017-06-12	2025-02-01	Twist Bioscience Corp	Methods for assembling continuous nucleic acids
CN111566125A (zh)	2017-09-11	2020-08-21	特韦斯特生物科学公司	Gpcr结合蛋白及其合成
CN111565834B (zh)	2017-10-20	2022-08-26	特韦斯特生物科学公司	用于多核苷酸合成的加热的纳米孔
JP7386161B2 (ja) *	2017-12-19	2023-11-24	ブレイズバイオサイエンス，インコーポレイテッド	腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
IL312616B2 (en)	2018-01-04	2025-08-01	Twist Bioscience Corp	Dna-based digital information storage
AU2019215191B2 (en) *	2018-02-02	2025-08-14	University Of Washington	Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
CN119286871A (zh)	2018-04-19	2025-01-10	查美特制药公司	合成rig-i样受体激动剂
EP3814497A4 (en)	2018-05-18	2022-03-02	Twist Bioscience Corporation	POLYNUCLEOTIDES, REAGENTS AND METHODS FOR NUCLEIC ACID HYBRIDIZATION
EP3863675A4 (en) *	2018-10-09	2023-09-06	Yale University	RIG-I AGONISTS AND METHODS OF USE THEREOF
EP3902816A4 (en)	2018-12-26	2022-09-14	Twist Bioscience Corporation	HIGH-PRECISION DE NOVO POLYNUCLEOTIDE SYNTHESIS
KR20210144698A (ko)	2019-02-26	2021-11-30	트위스트 바이오사이언스 코포레이션	항체 최적화를 위한 변이 핵산 라이브러리
CA3131689A1 (en)	2019-02-26	2020-09-03	Twist Bioscience Corporation	Variant nucleic acid libraries for glp1 receptor
WO2020225779A1 (en) *	2019-05-09	2020-11-12	Istituto Pasteur Italia - Fondazione Cenci Bolognetti	Rig-i agonists for cancer treatment and immunotherapy
EP3987019A4 (en)	2019-06-21	2023-04-19	Twist Bioscience Corporation	Barcode-based nucleic acid sequence assembly
WO2020260547A1 (en)	2019-06-27	2020-12-30	Rigontec Gmbh	Design method for optimized rig-i ligands
WO2021028439A1 (en)	2019-08-14	2021-02-18	Curevac Ag	Rna combinations and compositions with decreased immunostimulatory properties
CN115023440B (zh)	2019-09-23	2025-09-12	特韦斯特生物科学公司	结合CD3ε的抗体
US12091777B2 (en)	2019-09-23	2024-09-17	Twist Bioscience Corporation	Variant nucleic acid libraries for CRTH2
CA3155202A1 (en)	2019-10-23	2021-04-29	Arthur M. Krieg	Synthetic rig-i-like receptor agonists
AU2020400030B2 (en)	2019-12-09	2026-05-21	Twist Bioscience Corporation	Variant nucleic acid libraries for adenosine receptors
IL295759A (en)	2020-02-28	2022-10-01	Tallac Therapeutics Inc	Transglutaminase mediated coupling
EP3909612A1 (en)	2020-05-12	2021-11-17	Life Science Inkubator Betriebs GmbH & Co. KG	Composition of nanoparticles
CN115916978A (zh) *	2020-05-19	2023-04-04	哈德森医学研究所	寡核苷酸
WO2021237067A1 (en) *	2020-05-22	2021-11-25	President And Fellows Of Harvard College	Interferon- inducing oligonucleotide duplexes and methods of use
AU2021413862A1 (en) *	2020-12-30	2023-07-27	Transcode Therapeutics, Inc.	Template directed immunomodulation for cancer therapy
KR20240043747A (ko)	2021-07-02	2024-04-03	예일 유니버시티	암을 치료하기 위한 조성물 및 방법
JP2024532621A (ja)	2021-08-31	2024-09-05	イエールユニバーシティ	がんを治療するための組成物および方法
AU2023228912A1 (en)	2022-03-03	2024-09-19	Yale University	Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2026039779A1 (en)	2024-08-15	2026-02-19	Yale University	Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
WO2026047025A1 (en)	2024-08-27	2026-03-05	Rheinische Friedrich-Wilhelms-Universität Bonn	Photocontrollable conjugate, pharmaceutical composition and kit comprising the same, and uses thereof

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3534017A (en)	1967-03-14	1970-10-13	Kyowa Hakko Kogyo Kk	Process for the preparation of nucleoside-5'-diphosphates and triphosphates and mono- and oligo-nucleotidyl-nucleoside-5'-diphosphates and triphosphates
US4210746A (en)	1978-08-10	1980-07-01	National Research Development Corporation	Nucleotide inhibitor of protein synthesis
US4285605A (en)	1979-07-02	1981-08-25	International Business Machines Corporation	Escapement mechanism and backspace mechanism for a moving paper carriage typewriter having dual pitch capability
FR2471785A1 (fr) *	1979-12-21	1981-06-26	Fabre Sa Pierre	Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn
DE3023787A1 (de)	1980-06-25	1982-01-21	Studiengesellschaft Kohle mbH, 4330 Mülheim	Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
EP0081099A3 (en)	1981-12-04	1983-08-10	Sloan-Kettering Institute For Cancer Research	Capped oligonucleotide anti-viral agents
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5194428A (en)	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
WO1989008146A1 (en)	1988-02-26	1989-09-08	Worcester Foundation For Experimental Biology	Inhibition of htlv-iii by exogenous oligonucleotides
DE68929306T2 (de)	1988-04-27	2002-05-02	Isis Pharmaceutical, Inc.	H-Phosphonat Ribonucleotid-Derivate
JP2976436B2 (ja)	1988-04-27	1999-11-10	味の素株式会社	新規オリゴリボヌクレオチド誘導体及び抗ウイルス剤への使用
DE3907562A1 (de)	1989-03-09	1990-09-13	Bayer Ag	Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
WO1990014353A1 (en)	1989-05-18	1990-11-29	Microprobe Corporation	Crosslinking oligonucleotides
US5134066A (en)	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
EP0452457B1 (en)	1989-11-03	1997-08-20	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
US5149797A (en)	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
CA2078659A1 (en)	1990-03-21	1991-09-22	David J. Ecker	Reagents and methods for modulating gene expression through rna mimicry
US5292875A (en)	1990-04-20	1994-03-08	Lynx Therapeutics, Inc.	Method of synthesizing sulfurized oligonucleotide analogs
US5166195A (en)	1990-05-11	1992-11-24	Isis Pharmaceuticals, Inc.	Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
NZ239252A (en)	1990-08-09	1997-07-27	Genta Inc	Reagent for attaching a psoralen-containing moiety to an oligonucleotide(derivative); oligonucleotide(derivative)-psoralen conjugates
JPH06501843A (ja)	1990-08-14	1994-03-03	アイシス・ファーマシューティカルス・インコーポレーテッド	アンチセンスオリゴヌクレオチドによるインフルエンザａ型ウイルス，アン・アーバｈ２ｎ２株の阻害
US5271941A (en)	1990-11-02	1993-12-21	Cho Chung Yoon S	Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
DE4110085A1 (de)	1991-03-27	1992-10-01	Boehringer Ingelheim Int	2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
HUT66828A (en)	1991-03-27	1995-01-30	Res Corp Technologies Inc	Single-stranded circular oligonucleotides
US5646267A (en)	1991-08-05	1997-07-08	Polish Academy Of Sciences	Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US6369209B1 (en)	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en)	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
AU2874892A (en)	1991-10-15	1993-05-21	Isis Pharmaceuticals, Inc.	Oligonucleotides having chiral phosphorus linkages
NZ244820A (en)	1991-10-25	1994-01-26	Isis Pharmaceuticals Inc	Oligonucleotide inhibitor of epstein-barr virus.
FR2685346B1 (fr)	1991-12-18	1994-02-11	Cis Bio International	Procede de preparation d'arn double-brin, et ses applications.
US5644048A (en)	1992-01-10	1997-07-01	Isis Pharmaceuticals, Inc.	Process for preparing phosphorothioate oligonucleotides
CA2135646A1 (en)	1992-05-11	1993-11-25	Kenneth G. Draper	Method and reagent for inhibiting viral replication
US5606049A (en)	1992-06-03	1997-02-25	Genta Incorporated	Method of preparing 2'-O-methyl cytidine monomers useful in oligomer synthesis
US5652355A (en)	1992-07-23	1997-07-29	Worcester Foundation For Experimental Biology	Hybrid oligonucleotide phosphorothioates
ATE256143T1 (de)	1992-07-23	2003-12-15	Isis Pharmaceuticals Inc	2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen
TW244371B (pl)	1992-07-23	1995-04-01	Tri Clover Inc
US6346614B1 (en)	1992-07-23	2002-02-12	Hybridon, Inc.	Hybrid oligonucleotide phosphorothioates
IL108206A0 (en)	1993-01-06	1994-04-12	Univ Johns Hopkins	Oligomers having improved stability at acid ph
DK0677056T3 (da)	1993-01-25	1996-08-05	Hybridon Inc	Oligonukleotid-alkylphosphonater og -alkylphosphonothioater
EP0695306A1 (en)	1993-04-19	1996-02-07	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
FR2705099B1 (fr)	1993-05-12	1995-08-04	Centre Nat Rech Scient	Oligonucléotides phosphorothioates triesters et procédé de préparation.
JPH09500787A (ja)	1993-07-19	1997-01-28	ジェン−プローブ・インコーポレイテッド	蛋白生産、細胞増殖および／または感染症病原体の増殖に対するオリゴヌクレオチド阻害の促進
JPH0799976A (ja)	1993-09-30	1995-04-18	Takeda Chem Ind Ltd	修飾オリゴヌクレオチド
US5801235A (en)	1994-05-25	1998-09-01	Hybridon, Inc.	Oligonucleotides with anti-cytomegalovirus activity
AU2591495A (en)	1994-05-27	1995-12-21	Hybridon, Inc.	Use of oligonucleotide phosphorothioate for depleting complement and for reducing blood pressure
US5866699A (en)	1994-07-18	1999-02-02	Hybridon, Inc.	Oligonucleotides with anti-MDR-1 gene activity
ATE202569T1 (de)	1994-09-07	2001-07-15	Hybridon Inc	Prodrug-oligonukleotide
GB2293088B (en)	1994-09-16	1998-02-04	Alliedsignal Ltd	Guide loop height adjustment for vehicle passenger seat belts
US5591721A (en)	1994-10-25	1997-01-07	Hybridon, Inc.	Method of down-regulating gene expression
JPH08154687A (ja)	1994-12-12	1996-06-18	Yamanouchi Pharmaceut Co Ltd	アンチセンスオリゴヌクレオチド及び抗ウイルス剤
CA2207593A1 (en)	1994-12-13	1996-06-20	John Gustofson	Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
AU4514696A (en)	1994-12-22	1996-07-10	Hybridon, Inc.	Synthesis of stereospecific oligonucleotide phosphorothioates
US6111095A (en) *	1995-06-07	2000-08-29	Merck & Co., Inc.	Capped synthetic RNA, analogs, and aptamers
GB9511720D0 (en) *	1995-06-09	1995-08-02	Isis Innovation	Oligonucleotide phosphorylation method and products
US20040234999A1 (en)	1996-04-02	2004-11-25	Farrar Gwenyth Jane	Genetic suppression and replacement
US6127535A (en)	1997-11-05	2000-10-03	Ribozyme Pharmaceuticals, Inc.	Nucleoside triphosphates and their incorporation into oligonucleotides
EP1626086A2 (en)	1998-04-20	2006-02-15	Ribozyme Pharmaceuticals, Inc.	Double-stranded nucleic acid molecules with novel chemical compositions capable of modulating gene expression
JP2002512794A (ja)	1998-04-29	2002-05-08	リボザイム・ファーマシューティカルズ・インコーポレーテッド	ヌクレオチド三リン酸およびリボザイム内へのそれらの取り込み
EP1493818A3 (en)	1998-04-29	2006-02-15	Ribozyme Pharmaceuticals, Inc.	Nucleoside triphosphates and their incorporation into ribozymes
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6344323B1 (en) *	1998-09-16	2002-02-05	Vitagenix, Inc.	Compositions and methods for inhibiting cox-2 expression and treating cox-2 associated disorders by using cox-2 antisense oligonucleotides
EP1212416A2 (en)	1999-08-31	2002-06-12	Ribozyme Pharmaceuticals, Inc.	Nucleic acid based modulators of gene expression
IL148844A0 (en)	1999-09-27	2002-09-12	Coley Pharm Group Inc	Methods related to immunostimulatory nucleic acid-induced interferon
US20020028784A1 (en) *	2000-03-10	2002-03-07	Nest Gary Van	Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
DE10013600A1 (de)	2000-03-18	2002-01-10	Aventis Res & Tech Gmbh & Co	Reaktive Monomere für die Oligonucleotid- und Polynucleotidsynthese, modifizierte Oligonucleotide und Polynucleotiden und ein Verfahren zu deren Herstellung
US6686461B1 (en)	2000-03-22	2004-02-03	Solulink Bioscience, Inc.	Triphosphate oligonucleotide modification reagents and uses thereof
US20030077609A1 (en)	2001-03-25	2003-04-24	Jakobsen Mogens Havsteen	Modified oligonucleotides and uses thereof
US6900308B2 (en)	2001-07-16	2005-05-31	Isis Pharmaceuticals, Inc.	α-modified nucleoside triphosphates
WO2003012052A2 (en)	2001-07-30	2003-02-13	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Specific inhibition of gene expression by small double stranded rnas
FR2832154B1 (fr)	2001-11-09	2007-03-16	Centre Nat Rech Scient	Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US20030203868A1 (en)	2002-02-06	2003-10-30	Bushman Frederic D.	Inhibition of pathogen replication by RNA interference
RU2004128943A (ru)	2002-02-28	2005-04-20	Байота, Инк. (Us)	Средства, имитирующие нуклеотиды, и их пролекарственные формы
AU2003218181A1 (en) *	2002-03-15	2003-09-29	Multicell Immunotherapeutics, Inc.	Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
NZ535952A (en)	2002-04-04	2009-01-31	Coley Pharm Gmbh	Immunostimulatory G,U-containing oligoribonucleotides
US20050222061A1 (en)	2002-04-18	2005-10-06	Schulte Ralf W	Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
KR20050026384A (ko)	2002-04-26	2005-03-15	내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지	ＲＮＡｉ효과를 가지는 스템 루프 형 ＲＮＡ 분자 발현 시스템
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
CN1685063B (zh)	2002-08-12	2011-12-21	新英格兰生物实验室公司	与基因沉默相关的方法和组合物
US7109316B2 (en)	2002-08-23	2006-09-19	Ce Healthcare Bio-Sciences Corp.	Oligonucleotide tagged nucleoside triphosphates (OTNTPs) for genetic analysis
EP1546402A4 (en)	2002-09-04	2006-12-27	Johnson & Johnson Res Pty Ltd	METHODS OF USING DNADS IN INTERFERENT RNA MEDIATION (RNAi)
ES2456696T3 (es)	2002-09-11	2014-04-23	Genentech, Inc.	Composiciones y métodos para el diagnóstico y el tratamiento de tumores
EP2305813A3 (en)	2002-11-14	2012-03-28	Dharmacon, Inc.	Fuctional and hyperfunctional sirna
US7250496B2 (en)	2002-11-14	2007-07-31	Rosetta Genomics Ltd.	Bioinformatically detectable group of novel regulatory genes and uses thereof
US7217807B2 (en)	2002-11-26	2007-05-15	Rosetta Genomics Ltd	Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20130130231A1 (en)	2002-11-26	2013-05-23	Isaac Bentwich	Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7696334B1 (en)	2002-12-05	2010-04-13	Rosetta Genomics, Ltd.	Bioinformatically detectable human herpesvirus 5 regulatory gene
DE602004015064D1 (de)	2003-01-06	2008-08-28	Wyeth Corp	Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
WO2004074441A2 (en)	2003-02-19	2004-09-02	Government Of The United States Of America Represented By The Secretary Department Of Health And Human Services	Amplification or overexpression of mll septin-like fusion (msf) and septin9 and methods related thereto
CN1176937C (zh)	2003-02-21	2004-11-24	复旦大学附属中山医院	一种双链rna及其用途
US20040261149A1 (en)	2003-02-24	2004-12-23	Fauquet Claude M.	siRNA-mediated inhibition of gene expression in plant cells
EP1605961A4 (en)	2003-03-12	2009-11-11	Vasgene Therapeutics Inc	POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
US7381410B2 (en)	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004221760B2 (en)	2003-03-21	2010-03-18	Roche Innovation Center Copenhagen A/S	Short interfering RNA (siRNA) analogues
US20040220130A1 (en)	2003-03-24	2004-11-04	Robbins Paul D.	Compact synthetic expression vector comprising double-stranded DNA molecules and methods of use thereof
US8969543B2 (en)	2003-04-03	2015-03-03	Bioneer Corporation	SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US20050042641A1 (en)	2003-05-27	2005-02-24	Cold Spring Harbor Laboratory	In vivo high throughput selection of RNAi probes
US20050059044A1 (en)	2003-06-03	2005-03-17	Graham Michael Wayne	Double-stranded nucleic acid
WO2004108921A1 (ja)	2003-06-06	2004-12-16	Dainippon Sumitomo Pharma Co., Ltd.	核酸導入法
JP4874801B2 (ja)	2003-06-11	2012-02-15	イデラファーマシューティカルズインコーポレイテッド	安定化免疫調節オリゴヌクレオチド
FR2857013B1 (fr)	2003-07-02	2005-09-30	Commissariat Energie Atomique	Petits arn interferents specifiques des sous-unites alpha, alpha prime et beta de la proteine kinase ck2 et leurs applications
CN1882693B (zh) *	2003-09-15	2012-08-15	普洛体维生物治疗公司	聚乙二醇修饰的脂质化合物及其应用
AU2005213464A1 (en)	2004-02-06	2005-08-25	Wyeth	Diagnosis and therapeutics for cancer
US20050182005A1 (en)	2004-02-13	2005-08-18	Tuschl Thomas H.	Anti-microRNA oligonucleotide molecules
US20070265220A1 (en)	2004-03-15	2007-11-15	City Of Hope	Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2559955C (en)	2004-03-15	2016-02-16	City Of Hope	Methods and compositions for the specific inhibition of gene expression by double-stranded rna
AU2005323437B2 (en) *	2004-04-30	2011-10-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a C5-modified pyrimidine
CA2565685A1 (en)	2004-05-04	2005-12-15	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060035815A1 (en)	2004-05-04	2006-02-16	Nastech Pharmaceutical Company Inc.	Pharmaceutical compositions for delivery of ribonucleic acid to a cell
WO2005108573A2 (en)	2004-05-12	2005-11-17	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Method to induce rnai in prokaryotic organisms
AU2005259799A1 (en)	2004-07-02	2006-01-12	Protiva Biotherapeutics, Inc.	Immunostimulatory siRNA molecules and uses therefor
WO2006016574A1 (ja)	2004-08-12	2006-02-16	Kumamoto University	ＲＮＡｉを利用した抗腫瘍剤
DE602004032245D1 (de)	2004-11-16	2011-05-26	Qiagen Gmbh	Genabschaltung (Gene silencing) durch hybride Sens-DNA und Antisens-RNA Konstrukte, gekoppelt an ein Peptid zur erleichterten Aufnahme in Zellen
WO2006063252A2 (en)	2004-12-09	2006-06-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas
AR051895A1 (es)	2005-01-07	2007-02-14	Ard Of Higher Education On Beh	Metodo para disparar la interferencia de arn
US20100015041A1 (en)	2005-01-18	2010-01-21	Caltagirone Gaetano T	Class of Supramolecular Drug Molecules and Methods of Identification and Use Thereof
US20060178334A1 (en)	2005-02-04	2006-08-10	City Of Hope	Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon
US7998684B2 (en)	2005-02-07	2011-08-16	Takeda Pharmaceutical Company Limited	Screening method for an agent for treatment of neurodegenerative disease
JP4645234B2 (ja)	2005-03-03	2011-03-09	和光純薬工業株式会社	架橋剤、それを用いた架橋方法、遺伝子発現調節方法および遺伝子機能調査方法
PL1866414T3 (pl)	2005-03-31	2012-10-31	Calando Pharmaceuticals Inc	Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
JP2008537752A (ja)	2005-04-12	2008-09-25	イントラディグムコーポレイション	がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US7893244B2 (en)	2005-04-12	2011-02-22	Intradigm Corporation	Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20070066521A1 (en)	2005-04-13	2007-03-22	Fauquet Claude M	Short RNA-binding proteins
WO2006119643A1 (en)	2005-05-12	2006-11-16	Replicor Inc.	Anti-ocular angiogenesis molecules and their uses
WO2006122409A1 (en)	2005-05-16	2006-11-23	Replicor Inc.	Antimicrobial molecules and their uses
CN101213300B (zh) *	2005-06-01	2013-01-23	聚加转染股份有限公司	用于rna干扰的寡核苷酸及其生物学应用
WO2006130949A1 (en)	2005-06-08	2006-12-14	Replicor Inc.	Anti amyloid-related disease molecules and their uses
AU2006267841B2 (en)	2005-07-07	2011-12-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Nucleic acid agents for downregulating H19, and methods of using same
CN101287835A (zh)	2005-08-17	2008-10-15	株式会社百奥尼	用于siRNA细胞内输送的siRNA-亲水性聚合物结合物及其方法
JP2009507852A (ja)	2005-09-08	2009-02-26	エムディーアールエヌエー，インコーポレイテッド	リボ核酸の細胞への送達用医薬組成物
EP1764107A1 (en)	2005-09-14	2007-03-21	Gunther Hartmann	Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
EP1924284A1 (en)	2005-09-14	2008-05-28	Hartmann, Gunther	Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
EP1764108A1 (en)	2005-09-14	2007-03-21	Gunther Hartmann	Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
WO2007107304A2 (en)	2006-03-17	2007-09-27	Novosom Ag	An efficient method for loading amphoteric liposomes with nucleic acid active substances
WO2007038788A2 (en)	2005-09-29	2007-04-05	The Cleveland Clinic Foundation	Small interfering rnas as non-specific drugs
EP1948674A4 (en)	2005-11-02	2009-02-04	Protiva Biotherapeutics Inc	MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
CA2629664A1 (en)	2005-11-17	2007-08-02	Board Of Regents, The University Of Texas System	Modulation of gene expression by oligomers targeted to chromosomal dna
CA2634046A1 (en)	2005-12-12	2007-06-21	The University Of North Carolina At Chapel Hill	Micrornas that regulate muscle cell proliferation and differentiation
WO2007080457A2 (en)	2005-12-30	2007-07-19	Institut Gustave Roussy	Use of inhibitors of scinderin and/or of ephrin-a1 for treating tumors
CA2648585C (en)	2006-04-07	2017-07-25	Idera Pharmaceuticals, Inc.	Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
JP5558811B2 (ja)	2006-06-01	2014-07-23	トリリンクバイオテクノロジーズ	核酸増幅のための化学的に修飾されたオリゴヌクレオチドプライマー
JP2010507361A (ja)	2006-07-31	2010-03-11	キュアバックゲーエムベーハー	具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
JP2010500011A (ja)	2006-08-08	2010-01-07	ガンサーハートマン	５’リン酸オリゴヌクレオチドの構造および使用
EP2069500B1 (en)	2006-10-04	2014-09-24	Centre National De La Recherche Scientifique (Cnrs)	Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
EP2338499A1 (en)	2006-10-10	2011-06-29	Gunther Hartmann	5' triphosphate oligonucleotide induces anti-viral response
WO2008045576A2 (en)	2006-10-12	2008-04-17	Yijia Liu	Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
CN101190944A (zh)	2006-12-01	2008-06-04	北京诺赛基因组研究中心有限公司	人类新细胞因子及其用途
WO2008080091A2 (en)	2006-12-21	2008-07-03	Vical Incorporated	Activation of rig-i pathway
WO2008076127A1 (en)	2006-12-21	2008-06-26	Intradigm Corporation	Inhibitory polynucleotide compositions and methods for treating cancer
EP2111449B1 (en)	2007-01-16	2012-03-07	Yissum Research Development Company of the Hebrew University of Jerusalem	H19 silencing nucleic acid agents for treating rheumatoid arthritis
US9249423B2 (en)	2007-02-02	2016-02-02	Yale University	Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008099396A1 (en)	2007-02-15	2008-08-21	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Use of h19-silencing nucleic acid agents for treating restenosis
WO2008102728A1 (ja)	2007-02-19	2008-08-28	Kyoto University	核酸導入用導電性基板および核酸導入方法
MY173854A (en)	2007-03-13	2020-02-25	Malaysian Palm Oil Board	Expression regulatory elements
US7880063B2 (en)	2007-04-06	2011-02-01	Stine Seed Farm, Inc.	Soybean cultivar 6342078
US20090226525A1 (en)	2007-04-09	2009-09-10	Chimeros Inc.	Self-assembling nanoparticle drug delivery system
CN101088565A (zh)	2007-04-17	2007-12-19	华东师范大学	miRNA－34a的用途
WO2008134593A1 (en)	2007-04-25	2008-11-06	President And Fellows Of Harvard College	Molecular circuits
KR101738655B1 (ko)	2007-05-01	2017-05-22	로슈 이노베이션 센터 코펜하겐 에이/에스	Ｔｎｆ 슈퍼패밀리 수용체에 대한 스플라이스 스위칭 올리고머 및 질병 치료에 있어서의 그의 용도
AU2008262478B9 (en)	2007-05-29	2014-06-19	Aldevron, L.L.C.	Vectors and methods for genetic immunization
EP2178896A1 (en)	2007-07-31	2010-04-28	The Johns Hopkins University	Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US8367815B2 (en)	2007-08-28	2013-02-05	California Institute Of Technology	Modular polynucleotides for ligand-controlled regulatory systems
US20110082185A1 (en)	2007-09-17	2011-04-07	Ludwig Institute For Cancer Research Ltd.	Cancer-testis gene silencing agents and uses thereof
JP2011500005A (ja)	2007-10-11	2011-01-06	ユニバーシティーヘルスネットワーク	ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物
JP2011500023A (ja)	2007-10-12	2011-01-06	イントラダイムコーポレイション	インビトロ及びインビボでＶＥＧＦＲ１発現を低減するための治療用ｓｉＲＮＡ分子
DE102007052114B4 (de)	2007-10-30	2011-01-05	T2Cure Gmbh	Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
MX2010004984A (es)	2007-11-05	2010-07-29	Baltic Technology Dev Ltd	Uso de oligonucleotidos con bases modificadas en hibridacion de acidos nucleicos.
WO2009060281A2 (en)	2007-11-06	2009-05-14	Coley Pharmaceutical Gmbh	Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
ES2545963T3 (es)	2007-11-06	2015-09-17	Sirnaomics, Inc.	Terapéutica con ARNi multidirigidos para la cicatrización de heridas de la piel sin cicatriz
WO2009064590A2 (en)	2007-11-12	2009-05-22	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
ATE554186T1 (de)	2007-11-29	2012-05-15	Molecular Health Gmbh	Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung
US8357501B2 (en)	2007-11-29	2013-01-22	Molecular Health Gmbh	Tissue protective erythropoietin receptor (NEPOR) and methods of use
GB0725321D0 (en)	2007-12-31	2008-02-06	Syntaxin Ltd	Delivery vehicles
JP5721441B2 (ja)	2008-01-31	2015-05-20	キュアバックゲーエムベーハーＣｕｒｅｖａｃＧｍｂｈ	免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
US9738680B2 (en)	2008-05-21	2017-08-22	Rheinische Friedrich-Wilhelms-Universität Bonn	5′ triphosphate oligonucleotide with blunt end and uses thereof
DK2518150T3 (en)	2008-05-21	2015-12-07	Univ Bonn	5'Trip phosphate triphosphate oligonucleotide and uses thereof
CA2635187A1 (en)	2008-06-05	2009-12-05	The Royal Institution For The Advancement Of Learning/Mcgill University	Oligonucleotide duplexes and uses thereof
US20110152352A1 (en)	2008-06-10	2011-06-23	Tufts University	Smad proteins control drosha-mediated mirna maturation
CN101632833B (zh)	2008-07-25	2013-11-06	上海市计划生育科学研究所	一种前列腺癌相关的基因及其用途
WO2011028218A1 (en)	2009-09-02	2011-03-10	Alnylam Pharmaceuticals, Inc.	Process for triphosphate oligonucleotide synthesis
AU2009288078B2 (en)	2008-09-02	2014-10-30	Alnylam Pharmaceuticals, Inc.	Synthetic methods and derivatives of triphosphate oligonucleotides
WO2010042742A2 (en)	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
WO2010042751A2 (en)	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
WO2010042749A2 (en)	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
WO2010042755A2 (en)	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
CN102264898B (zh)	2008-10-23	2013-10-16	国立大学法人东京大学	微小rna的功能抑制方法
WO2010062502A1 (en)	2008-11-03	2010-06-03	University Of Utah Research Foundation	Carriers for the delivery of nucleic acids to cells and methods of use thereof
JP2012518997A (ja)	2009-02-26	2012-08-23	ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション	喫煙未経験者におけるマイクロｒｎａ、ならびに関連する材料および方法
US8987222B2 (en)	2009-04-08	2015-03-24	University Of Massachusetts	Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
WO2010120874A2 (en)	2009-04-14	2010-10-21	Chimeros, Inc.	Chimeric therapeutics, compositions, and methods for using same
US20100323018A1 (en)	2009-06-17	2010-12-23	Massachusetts Institute Of Technology	Branched DNA/RNA monomers and uses thereof
ES2386855T3 (es)	2009-07-09	2012-09-03	Marina Biotech, Inc.	Emulación de estructuras de lipoproteínas
US9238811B2 (en)	2009-07-14	2016-01-19	Northeastern University	siRNA phospholipid conjugate
WO2011011716A1 (en)	2009-07-23	2011-01-27	The Trustees Of Princeton University	Inhibitors of mtor kinase as anti-viral agents
EP2327783A1 (en)	2009-11-27	2011-06-01	Universitätsklinikum Freiburg	Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
DE202009015670U1 (de)	2009-11-30	2011-04-14	Mcairlaid's Vliesstoffe Gmbh & Co. Kg	Absorptionskörper zur Auflage auf Wunden
US20110247091A1 (en)	2010-03-26	2011-10-06	The Governors Of The University Of Alberta	Transgenic Cells and Chickens Expressing RIG-I
WO2011133559A2 (en)	2010-04-19	2011-10-27	University Of Georgia Research Foundation, Inc.	Alpha tubulin acetyltransferase
EP2385120A1 (en)	2010-05-04	2011-11-09	Justus-Liebig- Universitat Giessen	Use of anti-miRNA antisense oligonucleotides for the treatment of pulmonary hypertension
US9642873B2 (en)	2010-05-04	2017-05-09	Sirnaomics, Inc.	Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application
CN101974529B (zh)	2010-09-21	2013-04-03	南京大学（苏州）高新技术研究院	含自由三磷酸基团的TGF-β特异性siRNA及其应用
WO2012056440A1 (en)	2010-10-28	2012-05-03	Nanodoc Ltd.	COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
WO2012056441A1 (en)	2010-10-28	2012-05-03	Nanodoc Ltd.	Compositions and methods for specific cleavage of exogenous rna in a cell
CN102475892A (zh)	2010-11-22	2012-05-30	大连创达技术交易市场有限公司	作为制备抗癌药物的反义miRNA-210的用途
WO2012091523A2 (en)	2010-12-30	2012-07-05	Samyang Biopharmaceuticals Corporation	Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
US8461224B2 (en)	2011-03-04	2013-06-11	National Health Research Institutes	Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery
WO2012125987A2 (en)	2011-03-17	2012-09-20	Massachusetts Institute Of Technology	Delivery system
EP2508530A1 (en)	2011-03-28	2012-10-10	Rheinische Friedrich-Wilhelms-Universität Bonn	Purification of triphosphorylated oligonucleotides using capture tags
WO2013003887A1 (en)	2011-07-04	2013-01-10	Commonwealth Scientific And Industrial Research Organisation	Nucleic acid complex
EP2551354A1 (en)	2011-07-25	2013-01-30	Universität Heidelberg	Functionalization of RNA oligonucleotides
US20130189367A1 (en)	2011-07-29	2013-07-25	University Of Washington Through Its Center For Commercialization	Nanovectors for targeted gene silencing and cytotoxic effect in cancer cells
US9579394B2 (en)	2011-08-08	2017-02-28	Universitaet Regensburg	Polyanion nanocomplexes for therapeutic applications
WO2013053481A1 (de)	2011-10-11	2013-04-18	Secutech International Pte. Ltd.	Dimethylsulfoxid als lösungsmittel für nukleinsäuren
EP2765983A1 (de)	2011-10-11	2014-08-20	Hans Kosak	Zusammensetzung zur einbringung von nukleinsäuren in zellen
JP2014532400A (ja)	2011-10-31	2014-12-08	リボックス・ゲーエムベーハー	免疫賦活用の二本鎖ｒｎａ
EP2780455B1 (en)	2011-11-17	2017-07-05	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np)
US9193971B2 (en)	2012-04-10	2015-11-24	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods for the treatment of nonalcoholic steatohepatitis
US20130302252A1 (en)	2012-05-11	2013-11-14	University Of Washington Through Its Center For Commercialization	Polyarginine-coated magnetic nanovector and methods of use thereof
EP2712870A1 (en)	2012-09-27	2014-04-02	Rheinische Friedrich-Wilhelms-Universität Bonn	Novel RIG-I ligands and methods for producing them
US20140287023A1 (en)	2013-02-11	2014-09-25	Mcgill University	5'-triphosphate oligoribonucleotides

2007
- 2007-08-08 JP JP2009523199A patent/JP2010500011A/ja active Pending
- 2007-08-08 PT PT78015625T patent/PT2056845T/pt unknown
- 2007-08-08 SI SI200731977T patent/SI2056845T1/en unknown
- 2007-08-08 LT LTEP07801562.5T patent/LT2056845T/lt unknown
- 2007-08-08 WO PCT/EP2007/007024 patent/WO2008017473A2/en not_active Ceased
- 2007-08-08 EP EP07801562.5A patent/EP2056845B1/en not_active Revoked
- 2007-08-08 AU AU2007283022A patent/AU2007283022B2/en active Active
- 2007-08-08 EP EP17194752.6A patent/EP3342415B1/en active Active
- 2007-08-08 US US12/376,812 patent/US20100178272A1/en not_active Abandoned
- 2007-08-08 HU HUE07801562A patent/HUE037173T2/hu unknown
- 2007-08-08 ES ES17194752T patent/ES2911034T3/es active Active
- 2007-08-08 DK DK07801562.5T patent/DK2056845T3/da active
- 2007-08-08 PL PL07801562T patent/PL2056845T3/pl unknown
- 2007-08-08 EP EP22152906.8A patent/EP4082551A1/en active Pending
- 2007-08-08 ES ES07801562.5T patent/ES2647452T3/es active Active
- 2007-08-08 CA CA2660232A patent/CA2660232C/en active Active
2012
- 2012-05-08 US US13/466,747 patent/US9381208B2/en active Active
2014
- 2014-05-29 JP JP2014110956A patent/JP2014207906A/ja not_active Withdrawn
2015
- 2015-11-09 US US14/936,375 patent/US10238682B2/en active Active
2016
- 2016-08-04 JP JP2016153542A patent/JP2016189790A/ja not_active Withdrawn
2017
- 2017-11-15 CY CY20171101200T patent/CY1119608T1/el unknown
- 2017-12-18 JP JP2017241327A patent/JP6748629B2/ja active Active
2019
- 2019-01-11 JP JP2019003193A patent/JP7071299B2/ja active Active
2020
- 2020-12-01 JP JP2020199297A patent/JP7108011B2/ja active Active

Also Published As

Publication number	Publication date
US20160051573A1 (en)	2016-02-25
SI2056845T1 (en)	2018-02-28
LT2056845T (lt)	2017-11-27
PT2056845T (pt)	2017-11-17
EP2056845A2 (en)	2009-05-13
AU2007283022A1 (en)	2008-02-14
JP2021050214A (ja)	2021-04-01
JP7071299B2 (ja)	2022-05-18
HUE037173T2 (hu)	2018-08-28
EP4082551A1 (en)	2022-11-02
WO2008017473A3 (en)	2008-06-05
US10238682B2 (en)	2019-03-26
JP2019077709A (ja)	2019-05-23
JP7108011B2 (ja)	2022-07-27
DK2056845T3 (da)	2017-11-27
JP2016189790A (ja)	2016-11-10
ES2647452T3 (es)	2017-12-21
WO2008017473A2 (en)	2008-02-14
US9381208B2 (en)	2016-07-05
JP2014207906A (ja)	2014-11-06
AU2007283022B2 (en)	2011-07-28
US20100178272A1 (en)	2010-07-15
ES2911034T3 (es)	2022-05-17
CA2660232C (en)	2019-05-21
CY1119608T1 (el)	2018-04-04
CA2660232A1 (en)	2008-02-14
EP2056845B1 (en)	2017-10-11
JP2018082706A (ja)	2018-05-31
JP6748629B2 (ja)	2020-09-02
EP3342415B1 (en)	2022-01-26
EP3342415A1 (en)	2018-07-04
JP2010500011A (ja)	2010-01-07
US20120288476A1 (en)	2012-11-15

Publication	Publication Date	Title
HUE037173T2 (hu)	2018-08-28	5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
GB0625659D0 (en)	2007-01-31	Therapeutic compounds and their use
EP2021455A4 (en)	2014-01-01	SYSTEM FOR PREPARING CYTOBLOCS AND METHODS OF USE THEREOF
IL196956A0 (en)	2009-11-18	Aza-benzofuranyl compounds and methods of use
IL197060A0 (en)	2009-11-18	Aza-benzothiophenyl compounds and methods of use
PT2099796E (pt)	2011-09-06	Compostos azaindolilo e métodos de utilização
IL194028A0 (en)	2009-09-22	Tetrahydropyridothienopyrimidine compounds and methods of use thereof
PT2853293T (pt)	2018-02-13	Compostos de tionínio e a sua utilização
IL193693A0 (en)	2009-05-04	Purine compounds and methods of use thereof
ZA200806226B (en)	2009-09-30	4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrim-idines as jak 2 modulators and methods of use
ZA200700809B (en)	2008-11-26	Corrosion-inhibiting compositions and use thereof
PL2012805T3 (pl)	2014-01-31	Kompozycja lecznicza i jej zastosowanie
GB0611115D0 (en)	2006-07-19	Compounds and their use
PL2084272T3 (pl)	2016-10-31	Klonowanie, ekspresja oraz zastosowanie kwaśnych lizofosfolipaz
EP2100588A4 (en)	2011-01-19	PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST ALOPEY
EP1912630A4 (en)	2012-10-03	COMPOSITIONS AND METHODS FOR REDUCING POSTOPERATIVE PAIN
ZA200900896B (en)	2010-06-30	Aza-benzofuranyl compounds and methods of use
ZA200901009B (en)	2010-05-26	Aza-benzothiophenyl compounds and methods of use
GB0620695D0 (en)	2006-11-29	Composition and methods for the treatment of nurdegenerative disease
GB0605787D0 (en)	2006-05-03	"Preparation of oligonucleotides with photoswitchable properties
GB0619611D0 (en)	2006-11-15	Compounds and their use
GB0618309D0 (en)	2006-10-25	Compositions and methods for the treatment of disease
ZA200807956B (en)	2009-07-29	Purine compounds and methods of use thereof
GB0614538D0 (en)	2006-08-30	Therapeutic Compounds And Their Use
HU0600318D0 (en)	2006-06-28	Cholesterol-based fullerenlike body and biological or physical use of same